Atezolizumab + Ipatasertib + Paclitaxel + Placebo for Atezolizumab + Placebo for Ipatasertib
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Triple-Negative Breast Cancer
Conditions
Triple-Negative Breast Cancer
Trial Timeline
Nov 25, 2019 → Feb 28, 2023
NCT ID
NCT04177108About Atezolizumab + Ipatasertib + Paclitaxel + Placebo for Atezolizumab + Placebo for Ipatasertib
Atezolizumab + Ipatasertib + Paclitaxel + Placebo for Atezolizumab + Placebo for Ipatasertib is a phase 3 stage product being developed by Roche for Triple-Negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04177108. Target conditions include Triple-Negative Breast Cancer.
What happened to similar drugs?
1 of 6 similar drugs in Triple-Negative Breast Cancer were approved
Approved (1) Terminated (0) Active (5)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04177108 | Phase 3 | Completed |
Competing Products
20 competing products in Triple-Negative Breast Cancer